444-27-9

Basic information

• Product Name: Thiazolidine-4-carboxylic acid
• Synonyms: 4-carboxythiazolidine;4-thiazolidinecarboxylicacid;acidethiazolidine-4-carboxylique;gamma-thiaproline;hepalidine;heparegene;norgamem;nsc25855
• CAS NO: 444-27-9
• Molecular Formula: C₄H₇NO₂S
• Molecular Weight: 133.17
• EINECS: 207-146-6
• Product Categories: Heterocyclic Compounds;DETOXEPA;API
• Mol File: 444-27-9.mol
• Article Data: 23

Chemical Properties

• Melting Point: 196.5°C
• Boiling Point: 350.302 °C at 760 mmHg
• Flash Point: 165.657 °C
• Appearance: /solid
• Density: 1.226 (estimate)
• Refractive Index: 1.5480 (estimate)
• Storage Temp.: Room Temperature
• PKA: 2.09±0.20(Predicted)
• Water Solubility: 29.3g/L(21 oC)
• CAS DataBase Reference: Thiazolidine-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: Thiazolidine-4-carboxylic acid(444-27-9)
• EPA Substance Registry System: Thiazolidine-4-carboxylic acid(444-27-9)

Safety Data

• RIDADR: 2811
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 444-27-9(Hazardous Substances Data)

Usage

Originator

Hepaldine,Riker,France,1964

Uses

Timonacic is a derivative of Proline (P756050), a cyclic nonessential amino acid. Timonacic is a research molecule of interest with potential antineoplastic activities by acting on the cell membrane of tumour cells and causing reverse transformation to normal cells.

Definition

ChEBI: A sulfur-containing amino acid that is proline in which the methylene group at position 4 is replaced by a sulfur atom.

Manufacturing Process

Cysteine is first dissolved in distilled water which has been freed of oxygen by boiling. Formaldehyde of 30% (w/v) concentration is added while stirring and the temperature of the mixture rises, while the thiazolidine carboxylic acid begins crystallizing. The stirring is continued for 2 hours after which ethyl alcohol of 95% (w/v) concentration is added to induce further crystallization. The mixture is left to stand for 24 hours at 4°C. The mixture is then filtered with retention of a crude product, which is purified by recrystallization from boiling distilled water. The crystals are then dried at about 40°C. The free acid is then converted to the sodium salt with NaOH.

Therapeutic Function

Hepatoprotectant, Choleretic

InChI:InChI=1/C4H7NO2S/c6-4(7)3-1-8-2-5-3/h3,5H,1-2H2,(H,6,7)

Upstream product

• 50-00-0 formaldehyd 
• 52-89-1 l-cysteine hydrochloride 
• 52-89-1 L-cysteine hydrochloride 
• 32443-99-5 D-cysteine hydrochloride 
• 34592-47-7 L-thioproline 
• 114192-98-2 (2R,3R)-2,3-Dihydroxy-succinic acid; compound with (S)-thiazolidine-4-carboxylic acid 
• 10318-18-0 DL-cysteine hydrochloride 
• 444-27-9 (RS)-4-thiazolidinecarboxylic acid 
• 921-01-7 rac-cysteine 

Downstream Products

• 137441-54-4 C₃₁H₃₈N₂O₃S 
• 110822-04-3 N-(5-methyl-2-nitrobenzoyl)thiazolidine-4-carboxylic acid 
• 88381-44-6 N-nitrosothiazolidine-4-carboxylic acid 
• 640-61-9 N-methyl-p-toluenesulfonylamide 
• 5025-82-1 N-acetyl-thiazolidine-4-carboxylic acid 
• 131570-70-2 (4aS,7aS,8R,8aR)-8-Phenyl-hexahydro-cyclopenta[4,5]pyrrolo[1,2-c]thiazol-7-one 
• 131570-71-3 (1S,6R,7R,11R)-11-Phenyl-4-thia-2-aza-tricyclo[5.3.1.0^2,6]undecan-8-one 
• 110822-07-6 N-(5-methyl-2-nitrobenzyl)thiazolidine-4-carboxylic acid 
• 51977-23-2 6-phenyl-1H,3H-imidazo<1,5-c>thiazole-5,7-<6H,7aH>-dione 
• 86634-64-2 Tetrahydro-6-phenyl-5-thioxoimidazo[1,5-c]thiazol-7(3H)-one 
• 86625-91-4 6-methyl-1H,3H-imidazo<1,5-c>thiazole<6H,7aH>-5-one-7-thione 
• 89860-79-7 N-(2-nitrophenyl)thiazolidine-4-carboxylic acid 
• 110271-24-4 N-(3,4-dichlorobenzoyl)thiazolidine-4-carboxylic acid 
• 110822-06-5 N-(2-nitrobenzyl)thiazolidine-4-carboxylic acid 

Relevant articles and documents

PROCESS FOR PURIFYING (METH)ACRYLIC ACID

A process for producing a grade of (meth)acrylic acid having residual formaldehyde levels of under 100 parts per million.

HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR INHIBITING LIPID ACCUMULATION CONTAINING SAME

The present invention relates to a novel heterocyclic carboxylic acid derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient for inhibiting the accumulation of lipids in the body.

NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESS FOR THEIR PREPARATION

The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the dotted line [----] in the carbocyclic ring represents an optional double bond; R1 is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic ring, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl, CN, -COOR3, CONR3R4, -OR3, -NR3R4, or NR3COR3; R2 is hydrogen, cyano, COOH, or an isostere of a carboxylic acid (such as SO3H, CONOH, B(OH)2, PO3R3R4, SO2NR3R4, tetrazole, -COOR3, -CONR3R4, NR3COR4, or -COOCOR3).